Lymphoma

The Food and Drug Administration granted a priority review to a supplemental biologics license application for Kymriah (tisagenlecleucel) to be used to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma who either relapse or are not eligible for an autologous stem cell transplant.

Kevin explains the delights of being both a cancer patient and an adult.

The researchers noted that physical activity plays an important role in lymphoma survivorship, and the data may provide rationale for a clinical trial to evaluate exercise intervention in this patient population.

NextSource Pharma, a small pharmaceutical company based in Florida, acquired the drug lomustine from Bristol-Myers Squibb, changed its brand name to Gleostine, and changed the price – by about 1,400 percent.

Patients with blood cancers are at an increased risk for multiple hospital readmissions. However, multidisciplinary teams and patients can work together to identify predictors and avoid these occurrences.

Adcetris (brentuximab vedotin) was granted a priority review to a supplemental biologics license application (sBLA) by the Food and Drug Administration (FDA) to be used in combination with Adriamycin, vinblastine and dacarbazine (AVD) to treat patients with classical Hodgkin lymphoma in the frontline setting, according to Seattle Genetics, the company developing the drug.

A young cancer survivor shares insight on what it was like being diagnosed with non-Hodgkin lymphoma, and how she deals in day-to-day life.

Of every complication caused from cancer and its treatments, nausea has been the worst for my sister. It has caused pain, discomfort and was the number one reason she returned to the emergency room. No matter what medications were dosed, whether it was orally or by IV, or how much they gave to her, so often, nothing ever seemed to work.

Patients with blood cancers typically value time spent at home in their end-of-life care, however, health care systemts do not always prioritize this in their own quality measures.

Patients aged 75 years or older diagnosed with hematologic malignancies appear significantly underrepresented in clinical trials submitted to the U.S. Food and Drug Administration (FDA), according to a retrospective analysis.

From diagnosis to remission, my sister had cancer for nearly three years. Because of that, the cancer dates that mark my calendar are plentiful. I can recall most of them from memory without a second glance. While I was recently going through my old planners, I noticed just how many dates are filled with notations of cancer.

Keytruda (pembrolizumab) was granted a priority review to a supplemental biologics license application (sBLA) to be used to treat adult and pediatric patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL).

Treatment decisions are not always easy, but this is one I don't regret making.

Cancer treatment isn't what it used to be, and it is important that patients and their loved ones understand that.

I know I’ll never be Thor, but I do know the best way to ingest fungus.

The Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone, for the first-line treatment of patients with advanced follicular lymphoma, according to Genentech, the manufacturer of the drug.

While recent advances in hematology are exciting, they open the door to more questions.

A new drug was approved for patients with cutaneous T-cell lymphoma (CTCL).

Calquence (acalabrutinib) was granted an accelerated approval by the FDA to treat adult patients with mantle cell lymphoma (MCL) following at least one prior therapy. The approval was based on objective response rates (ORR) in a single-arm trial.

Cobra, baseball cards and two guys who always let me know I wasn't dead.

Yescarta was granted FDA approval for use in adults with relapsed or refractory non-Hodgkin lymphoma. This is only the second CAR T-cell therapy ever approved.

Adcetris (brentuximab vedotin) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the frontline treatment of patients who have classical Hodgkin lymphoma

Aliqopa (copanlisib) was granted FDA approval for the treatment of patients with relapsed follicular lymphoma who have received at least two least prior systemic therapies.

The Food and Drug Administration (FDA) granted a priority review to a supplemental biologics license application (sBLA) for Gazyva (obinutuzumab) to be used in combination with chemotherapy for first-line treatment of patients who have follicular lymphoma, according to Genentech, the manufacturer of the drug.

A type of CAR-T cell therapy is showing promise in a phase 1 study for patients with Hodgkin lymphoma and ALCL.

To prevent family conflicts over cancer treatment decisions, experts recommend a series of frank conversations.

Acalabrutinib was granted a priority review to a new drug application (NDA) to be used to treat patients with mantle cell lymphoma (MCL) who have had previous treatment, according to AstraZeneca, the manufacturer of the drug.

A recent study found that children of older parents may have an increased risk of certain types of cancers.

Keytruda (pembrolizumab) and Rituxan (rituximab) showed promising results for patients with follicular lymphoma in a recent study.